In cancers such as breast and pancreatic cancers, Signature 3 is strongly associated with germline or somatic BRCA1/BRCA2 mutations, which are well-established indicators for susceptibility to PARP inhibitors (20, 21). This evidence concerns the gene BRCA2 and cancer.